New combo therapy aims to keep prostate cancer in check longer
NCT ID NCT01786265
First seen Mar 03, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study looks at men whose prostate cancer has returned after surgery or radiation. It compares standard hormone therapy (which lowers testosterone) to the same therapy plus abiraterone and prednisone, which further block testosterone production. The goal is to see if the combination keeps PSA levels very low for longer. About 310 men will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.